Comparison of balloon-expandable vs. ...
Type de document :
Article dans une revue scientifique: Article original
DOI :
PMID :
URL permanente :
Titre :
Comparison of balloon-expandable vs. Self-expandable valves in patients undergoing transfemoral transcatheter aortic valve implantation: from the center-collaboration
Auteur(s) :
Vlastra, Wieneke [Auteur]
Chandrasekhar, Jaya [Auteur]
Munoz-Garcia, Antonio J. [Auteur]
Tchetche, Didier [Auteur]
De Brito, Fabio Sandoli [Auteur]
Barbanti, Marco [Auteur]
Kornowski, Ran [Auteur]
Latib, Azeem [Auteur]
D''''onofrio, Augusto [Auteur]
Ribichini, Flavio [Auteur]
Baan, Jan [Auteur]
Tijssen, Jan G P. [Auteur]
Trillo-Nouche, Ramiro [Auteur]
Dumonteil, Nicolas [Auteur]
Abizaid, Alexandre [Auteur]
Sartori, Samantha [Auteur]
D''''errigo, Paola [Auteur]
Tarantini, Giuseppe [Auteur]
Lunardi, Mattia [Auteur]
Orvin, Katia [Auteur]
Pagnesi, Matteo [Auteur]
Del Valle, Raquel [Auteur]
Modine, Thomas [Auteur]
Troubles cognitifs dégénératifs et vasculaires - U 1171 - EA 1046 [TCDV]
Troubles cognitifs dégénératifs et vasculaires - U1171
Troubles cognitifs dégénératifs et vasculaires - U 1171 - EA 1046 [TCDV]
Dangas, George [Auteur]
Mehran, Roxana [Auteur]
Piek, Jan J. [Auteur]
Delewi, Ronak [Auteur]
Chandrasekhar, Jaya [Auteur]
Munoz-Garcia, Antonio J. [Auteur]
Tchetche, Didier [Auteur]
De Brito, Fabio Sandoli [Auteur]
Barbanti, Marco [Auteur]
Kornowski, Ran [Auteur]
Latib, Azeem [Auteur]
D''''onofrio, Augusto [Auteur]
Ribichini, Flavio [Auteur]
Baan, Jan [Auteur]
Tijssen, Jan G P. [Auteur]
Trillo-Nouche, Ramiro [Auteur]
Dumonteil, Nicolas [Auteur]
Abizaid, Alexandre [Auteur]
Sartori, Samantha [Auteur]
D''''errigo, Paola [Auteur]
Tarantini, Giuseppe [Auteur]
Lunardi, Mattia [Auteur]
Orvin, Katia [Auteur]
Pagnesi, Matteo [Auteur]
Del Valle, Raquel [Auteur]
Modine, Thomas [Auteur]

Troubles cognitifs dégénératifs et vasculaires - U 1171 - EA 1046 [TCDV]
Troubles cognitifs dégénératifs et vasculaires - U1171
Troubles cognitifs dégénératifs et vasculaires - U 1171 - EA 1046 [TCDV]
Dangas, George [Auteur]
Mehran, Roxana [Auteur]
Piek, Jan J. [Auteur]
Delewi, Ronak [Auteur]
Titre de la revue :
European heart journal
Nom court de la revue :
Eur. Heart J.
Date de publication :
2018-12-24
ISSN :
1522-9645
Mot(s)-clé(s) en anglais :
Stroke
Medtronic CoreValve
Transcatheter aortic valve implantation
Transcatheter aortic valve replacement
Balloon-expandable valve
Self-expandable valve
Edwards Sapien
Medtronic CoreValve
Transcatheter aortic valve implantation
Transcatheter aortic valve replacement
Balloon-expandable valve
Self-expandable valve
Edwards Sapien
Discipline(s) HAL :
Sciences du Vivant [q-bio]
Résumé en anglais : [en]
The aim of this study was to compare clinical outcomes of patients undergoing transfemoral transcatheter aortic valve implantation (TAVI) with balloon-expandable (BE) valves vs. self-expandable (SE) valves. Transcatheter ...
Lire la suite >The aim of this study was to compare clinical outcomes of patients undergoing transfemoral transcatheter aortic valve implantation (TAVI) with balloon-expandable (BE) valves vs. self-expandable (SE) valves. Transcatheter aortic valve implantation is a minimally invasive and lifesaving treatment in patients with aortic valve stenosis. Even though BE-valves and SE-valves are both commonly used on a large scale, adequately sized trials comparing clinical outcomes in patients with severe aortic valve stenosis treated with BE-valves compared with SE-valves are lacking. In this CENTER-collaboration, data from 10 registries or clinical trials, selected through a systematic search, were pooled and analysed. Propensity score methodology was used to reduce treatment selection bias and potential confounding. The primary endpoints were mortality and stroke at 30 days follow-up in patients treated with BE-valves compared with SE-valves. Secondary endpoints included clinical outcomes, e.g. bleeding during hospital admission. All outcomes were split for early-generation BE-valves compared with early-generation SE-valves and new-generation BE-valves with new-generation SE-valves. The overall patient population (N = 12 381) included 6239 patients undergoing TAVI with BE-valves and 6142 patients with SE-valves. The propensity matched population had a mean age of 81 ± 7 years and a median STS-PROM score or 6.5% [interquartile range (IQR) 4.0-13.0%]. At 30-day follow-up, the mortality rate was not statistically different in patients undergoing TAVI with BE-valves compared with SE-valves [BE: 5.3% vs. SE: 6.2%, relative risk (RR) 0.9; 95% confidence interval (CI) 0.7-1.0, P = 0.10]. Stroke occurred less frequently in patients treated with BE-valves (BE: 1.9% vs. SE: 2.6%, RR 0.7; 95% CI 0.5-1.0, P = 0.03). Also, patients treated with BE-valves had a three-fold lower risk of requiring pacemaker implantation (BE: 7.8% vs. SE: 20.3%, RR 0.4; 95% CI 0.3-0.4, P < 0.001). In contrast, patients treated with new-generation BE-valves more frequently experienced major and life-threatening bleedings compared with new-generation SE-valves (BE: 4.8% vs. SE: 2.1%, RR 2.3; 95% CI 1.6-3.3, P < 0.001). In this study, which is the largest study to compare valve types in TAVI, we demonstrated that the incidence of stroke and pacemaker implantation was lower in patients undergoing transfemoral TAVI with BE-valves compared with SE-valves. In contrast, patients treated with new-generation BE-valves more often suffered from major or life-threatening bleedings than patients with new-generation SE-valves. Mortality at 30-days was not statistically different in patients treated with BE-valves compared with SE-valves. This study was a propensity-matched analysis generated from observational data, accordingly current outcomes will have to be confirmed in a large scale randomized controlled trial.Lire moins >
Lire la suite >The aim of this study was to compare clinical outcomes of patients undergoing transfemoral transcatheter aortic valve implantation (TAVI) with balloon-expandable (BE) valves vs. self-expandable (SE) valves. Transcatheter aortic valve implantation is a minimally invasive and lifesaving treatment in patients with aortic valve stenosis. Even though BE-valves and SE-valves are both commonly used on a large scale, adequately sized trials comparing clinical outcomes in patients with severe aortic valve stenosis treated with BE-valves compared with SE-valves are lacking. In this CENTER-collaboration, data from 10 registries or clinical trials, selected through a systematic search, were pooled and analysed. Propensity score methodology was used to reduce treatment selection bias and potential confounding. The primary endpoints were mortality and stroke at 30 days follow-up in patients treated with BE-valves compared with SE-valves. Secondary endpoints included clinical outcomes, e.g. bleeding during hospital admission. All outcomes were split for early-generation BE-valves compared with early-generation SE-valves and new-generation BE-valves with new-generation SE-valves. The overall patient population (N = 12 381) included 6239 patients undergoing TAVI with BE-valves and 6142 patients with SE-valves. The propensity matched population had a mean age of 81 ± 7 years and a median STS-PROM score or 6.5% [interquartile range (IQR) 4.0-13.0%]. At 30-day follow-up, the mortality rate was not statistically different in patients undergoing TAVI with BE-valves compared with SE-valves [BE: 5.3% vs. SE: 6.2%, relative risk (RR) 0.9; 95% confidence interval (CI) 0.7-1.0, P = 0.10]. Stroke occurred less frequently in patients treated with BE-valves (BE: 1.9% vs. SE: 2.6%, RR 0.7; 95% CI 0.5-1.0, P = 0.03). Also, patients treated with BE-valves had a three-fold lower risk of requiring pacemaker implantation (BE: 7.8% vs. SE: 20.3%, RR 0.4; 95% CI 0.3-0.4, P < 0.001). In contrast, patients treated with new-generation BE-valves more frequently experienced major and life-threatening bleedings compared with new-generation SE-valves (BE: 4.8% vs. SE: 2.1%, RR 2.3; 95% CI 1.6-3.3, P < 0.001). In this study, which is the largest study to compare valve types in TAVI, we demonstrated that the incidence of stroke and pacemaker implantation was lower in patients undergoing transfemoral TAVI with BE-valves compared with SE-valves. In contrast, patients treated with new-generation BE-valves more often suffered from major or life-threatening bleedings than patients with new-generation SE-valves. Mortality at 30-days was not statistically different in patients treated with BE-valves compared with SE-valves. This study was a propensity-matched analysis generated from observational data, accordingly current outcomes will have to be confirmed in a large scale randomized controlled trial.Lire moins >
Langue :
Anglais
Audience :
Internationale
Vulgarisation :
Non
Établissement(s) :
CHU Lille
CNRS
Inserm
Université de Lille
CNRS
Inserm
Université de Lille
Collections :
Équipe(s) de recherche :
Troubles cognitifs dégénératifs et vasculaires
Date de dépôt :
2019-11-27T14:31:12Z